Options360

REGN Q3 earnings 11/3 @ 6:30am

Short
NASDAQ:REGN   Regeneron Pharmaceuticals, Inc.
REGN Q3 September 2022 earnings are on 11/3 at 6:30am. Regeneron Pharmaceuticals (REGN) reported Q2 June 2022 earnings of $9.77 per share on revenue of $2.9 billion. The consensus earnings estimate was $8.53 per share on revenue of $2.8 billion. Revenue fell 44.4% compared to the same quarter a year ago. REGN short entry based on its $754 all time high major resistance level which it didn't even break through during the global covid pandemic in 2020. Plus, the nearest support going into earnings on 11/3 is the SMA50 around $663. Any short term pop up is an opportunity to get a higher strike put with a further dated expiry imo.

Q3 September 2022 Consensus:
EPS = $8.77
Revenue = $2.82 B

SMA50 = 663.67
SMA100 = 634.61
SMA150 = 649.19
SMA200 = 641.40

52week high = 754.67
52week low = 538.01

Do your own due diligence, your risk is 100% your responsibility. This is for educational and entertainment purposes only. You win some or you learn some. Consider being charitable with some of your profit to help humankind. Good luck and happy trading friends...

*3x lucky 7s of trading*

7pt Trading compass:
Price action, entry/exit
Volume average/direction
Trend, patterns, momentum
Newsworthy current events
Revenue
Earnings
Balance sheet

7 Common mistakes:
+5% portfolio trades, capital risk management
Beware of analyst's motives
Emotions & Opinions
FOMO : bad timing, the market is ruthless, be shrewd
Lack of planning & discipline
Forgetting restraint
Obdurate repetitive errors, no adaptation

7 Important tools:
Trading View app!, Brokerage UI
Accurate indicators & settings
Wide screen monitor/s
Trading log (pencil & graph paper)
Big, organized desk
Reading books, playing chess
Sorted watch-list

Checkout my indicators:
Fibonacci VIP - volume
Fibonacci MA7 - price
pi RSI - trend momentum
TTC - trend channel
AlertiT - notification
tickerTracker - MFI Oscillator
www.tradingview.com/u/growerik/

Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.